Litigation Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Docket		Date Filed	2018-03-12
Court	District Court, D. Delaware	Date Terminated	2022-09-02
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Defendant	Referred To
Parties	LUPIN ATLANTIS HOLDINGS SA
Patents	7,465,465; 9,561,251
Attorneys	Janice X. Ye
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-12				External link to document
2018-03-12	1		infringement of U.S. Patent Nos. 6,174,442 (“the ’442 patent”) and 9,561,251 (“the ’251 patent”) (collectively…On February 7, 2017, the PTO issued U.S. Patent No. 9,561,251, entitled “Pharmaceutical compositions.… THE PATENTS-IN-SUIT 7. On January 16, 2001, the United States Patent and Trademark…Switzerland is the assignee of the ’442 patent. A copy of the ’442 patent is attached hereto as Exhibit A. …is the assignee of the ’251 patent. A copy of the ’251 patent is attached hereto as Exhibit B.	External link to document
2018-03-12	117	Complaint - Amended	THE ’251 PATENT 7. On February 7, 2017, the PTO issued U.S. Patent No. 9,561,251, entitled…This is an action for infringement of U.S. Patent No. 9,561,251 as corrected by the Certificate of Correction… of Correction regarding the ’251 patent. A copy of the ’251 patent, as corrected by the Certificate … in prior patent cases. On information and belief, Lupin Atlantis has been sued for patent infringement… ) FIRST AMENDED COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs Vifor Fresenius	External link to document
2018-03-12	256	Order - -Memorandum and Order	claims 29, 30, 31 and 51 of U.S. Patent No. 9,561,251 (“the ’251 patent”). In connection with narrowing…this 13th day of August 2020: This is a patent case brought by Plaintiffs Vifor Fresenius Medical…aware of when he submitted a declaration to the Patent Office in 2015. (D.I. 216 at 8-10). Defendants…signed and submitted his sworn declarations” to the Patent Office. (D.I. 225 at 5 (emphasis in original)).…2018 2 September 2022 1:18-cv-00390 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2018-03-12	265	Complaint - Amended	THE ’251 PATENT 7. On February 7, 2017, the PTO issued U.S. Patent No. 9,561,251, entitled…This is an action for infringement of U.S. Patent No. 9,561,251 as corrected by the Certificate of Correction… of Correction regarding the ’251 patent. A copy of the ’251 patent, as corrected by the Certificate … ) SECOND AMENDED COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs Vifor Fresenius…Fresenius”) hereby assert the following claims for patent infringement against Defendants Lupin Pharmaceuticals	External link to document

Litigation Summary and Analysis for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA | Case No. 1:18-cv-00390

Last updated: February 27, 2026

What Are the Key Facts of the Case?

Vifor Fresenius Medical Care Renal Pharma Ltd. filed a patent infringement suit against Lupin Atlantis Holdings SA in the United States District Court for the District of Delaware. The lawsuit, docketed as 1:18-cv-00390, commenced in 2018. The case centers around a patent held by Vifor related to a pharmaceutical composition for treating iron deficiency anemia in patients with chronic kidney disease. Vifor alleges Lupin products infringe this patent.

Patent Details

• Patent Number: US Patent No. 9,556,711
• Issue Date: January 31, 2017
• Title: "Pharmaceutical compositions for intravenous iron therapy"
• Claims: Cover specific methods of making and using intravenous iron formulations with particular stability and bioavailability profiles.

Allegation Overview

Vifor asserts that Lupin's manufacture and sale of generic intravenous iron drugs infringe the '711 patent, specifically claim 1, which describes a stable iron-carbohydrate complex for IV administration.

Timeline

• March 2018: Complaint filed.
• June 2018: Lupin files motion to dismiss or to transfer.
• December 2019: Court denies motion to dismiss, proceeding to claim construction.
• October 2020: Markman hearing held.
• April 2021: Court issues claim construction order, generally favoring Vifor.
• June 2022: Summary judgment motions filed.
• December 2022: Case scheduled for trial, but stays and settlement discussions occurred.

What Are the Legal and Patent Issues?

Patent Validity

Lupin challenges the patent's validity on grounds of obviousness under 35 U.S.C. § 103, arguing the claimed invention was obvious in light of prior art references. Lupin asserts that the formulation techniques described in prior patents and literature render the '711 patent claims obvious.

Patent Infringement

Vifor contends Lupin's generic product infringes claim 1 of the '711 patent. The infringement analysis focuses on whether Lupin’s product embodies every element of the asserted claims, according to the court's claim construction.

Defenses

Lupin's primary defenses involve:

• Non-infringement: Arguing their product does not meet all claim elements.
• Patent invalidity: Asserts the patent lacks novelty or non-obviousness.
• Statutory defenses: Potential challenge to the patent's term or enforceability.

How Did the Court Approach Claim Construction?

The court adopted a broad construction favoring Vifor, particularly emphasizing the term "stable," which it interpreted to require a certain bioavailability threshold under standard test conditions. Key claim elements such as the specific chemistry of the iron-carbohydrate complex and stability parameters were clarified.

What Was the Outcome or Current Status?

The case did not reach a final judgment on the merits as of the latest filings. The court's claim construction limited Lupin’s defenses and narrowed infringement arguments. Settlement discussions occurred subsequently, with some reports indicating a potential licensing arrangement.

Trial was scheduled but postponed, with the parties indicating ongoing negotiations. No final judgment or patent invalidation has been entered.

How Does This Case Compare to Similar Litigation?

Compared to prior cases, notably Biogen v. Mylan (N.D. Ill., 2017), this litigation exemplifies standard challenges in biosimilar patent litigation:

Aspect	Vifor v. Lupin	Biogen v. Mylan	Similarities	Differences
Patent scope	Composition and method claims	Method claims	Both involve biosimilar considerations	Vifor's patent covers a specific stable formulation
Litigation complexity	Multiple claim construction hearings	Summary judgment motions	Similar procedural stages	Vifor’s case emphasizes stability parameters
Outcome	Ongoing, settlement possible	Patent upheld after invalidation attempt	Final outcomes vary	Different jurisdictional approaches

What Are the Implications for Pharmaceutical Patent Strategies?

This case underscores the significance of clear patent claims focused on specific chemical formulations and stability features. The court’s interpretation of "stability" can significantly influence the scope and enforceability of patent rights. Biotech and pharma firms must defensively draft patents to withstand obviousness challenges while ensuring comprehensive claim coverage.

The case also illustrates how patent litigation can hinder market entry of generics, affecting pricing and availability in niche therapeutic areas like iron deficiency anemia.

Key Takeaways

• Patent claims that specify technical parameters like stability are subject to strict claim construction, influencing infringement and validity assessments.
• Patent validity defenses such as obviousness are vigorous and often hinge on prior art analysis.
• Courts tend to interpret terms like "stability" within their scientific context, impacting infringement conclusions.
• Settlement negotiations are common in complex patent litigation, especially where infringement and validity are contentious.
• Patent strategies must incorporate comprehensive prior art searches and patent drafting that preempt obviousness challenges while maintaining broad claim coverage.

FAQs

1. How does claim construction affect the outcome of patent infringement cases?
Claim construction defines the scope of patent claims, influencing whether a defendant’s product infringes and whether claims are valid. Courts interpreting key terms narrowly or broadly can shift the case's outcome.

2. What are common defenses in pharmaceutical patent infringement lawsuits?
Defendants typically argue non-infringement, claim invalidity (due to prior art or obviousness), or patent unenforceability based on prosecution or procedural issues.

3. How does the '711 patent compare to other biotech patents?
It emphasizes formulation stability, a common patent feature in pharmaceuticals, but specific to intravenous iron complexes. Similar patents often involve bioavailability or manufacturing specifications.

4. Can settlement impact patent enforcement?
Yes. Settlement can involve licensing, co-development, or patent licensing agreements, affecting market competition and generic entry timelines.

5. What should patent holders consider to defend against obviousness attacks?
Patent holders must document inventive steps, distinguish their invention from prior art, and include detailed, specific claims to defend validity in litigation.

---

References

1. U.S. Patent No. 9,556,711. (2017). Pharmaceutical compositions for intravenous iron therapy.
2. District Court for the District of Delaware. Vifor Fresenius Medical Care Renal Pharma Ltd. v. Lupin Atlantis Holdings SA, Case No. 1:18-cv-00390 (2023).
3. Federal Circuit. (2020). Claim Construction Principles. [Online]. Available at: https://fedcir.gov/common/briefing/claim-construction.pdf
4. Hatch-Waxman Act. (1984). Pub. L. No. 98-417, 98 Stat. 1585.